SM Lin, ML Yu, CM Lee, RN Chien, IS Sheen, … - Journal of hepatology, 2007 - Elsevier The cumulative incidence at the end of 15 years of follow-up (median 6.8 years,
range 1.1–16.5 years) in the IFN-treated patients and controls was: HBeAg
seroconversion 74.6% vs. 51.7% (P = 0.031); hepatitis B surface antigen ... Cited by 76 - Related articles - All 10 versions
- ►higadocolombia.org [PDF] T Shaw, A Bartholomeusz, S Locarnini - Journal of hepatology, 2006 - Elsevier Besides interferon, only two drugs—lamivudine and adefovir dipivoxil—are
approved as first-line therapy for chronic hepatitis B (CHB) in the EU [1] and
[2]. Each is a nucleoside or nucleotide analogue that acts mainly as a ... Cited by 63 - Related articles - All 9 versions
RP Perrillo - Hepatology, 2006 - interscience.wiley.com The practicing clinician is currently faced with a number of treatment options
for chronic hepatitis B. Beginning in 1998 with the licensing of lamivudine and
subsequently adefovir, the treatment paradigm shifted from 4 to 6 months of ... Cited by 51 - Related articles - BL Direct - All 4 versions
GV Papatheodoridis, S Manolakopoulos, G … - The Lancet Infectious Diseases, 2007 - Elsevier Currently available options for the treatment of chronic hepatitis B virus (HBV)
infection include standard and pegylated interferon alfa and four oral antiviral
agents (lamivudine, adefovir, entecavir, and telbivudine). These treatment ... Cited by 41 - Related articles - All 17 versions
F Kanwal, M Farid, P Martin, G Chen, IM … - American Journal of Gastroenterology, 2006 - sovegastro.com Fasiha Kanwal, MD, MSHS,1–4 Mary Farid, DO,1,3 Paul Martin, MD,6 Gary Chen,
MD,6 Ian M. Gralnek, MD, MSHS,2,3 Gareth S. Dulai, MD, MSHS,2,3 and Brennan MR
Spiegel, MD, MSHS1–4 1Division of Gastroenterology, VA Greater Los ... Cited by 28 - Related articles - View as HTML - BL Direct - All 9 versions
GC Farrell, NC Teoh - Intern Med J, 2006 - npue.edu.tw Management of chronic hepatitis B virus infection: a new era of ... Department
of Gastroenterology and Hepatology, The Canberra Hospital and Department of
Medicine, Australian National University, Canberra, Australian Capital ... Cited by 28 - Related articles - View as HTML - All 4 versions
- ►annals.org [PDF] DW Hutton, D Tan, SK So, ML Brandeau - Annals of Internal Medicine, 2007 - Am Coll Physicians Background: As many as 10% of Asian and Pacific Islander adults in the United
States are chronically infected with hepatitis B virus (HBV), and up to two
thirds are unaware that they are infected. Without proper medical ... Cited by 22 - Related articles - BL Direct - All 9 versions
H Zhao, F Kurbanov, MB Wan, YK Yin, JQ Niu … - Clinical Infectious Diseases, 2007 - UChicago Press Featured in New York Times "Searching the Web for Flu Outbreaks" November 28,
2008 Using Internet Searches for Influenza Surveillance Philip M. Polgreen,
Yiling Chen, David M. Pennock, and Forrest D. Nelson One study, published ... Cited by 17 - Related articles - BL Direct - All 4 versions
P Del Poggio, M Zaccanelli, M Oggionni, S … - 世界胃肠病学杂志: 英文版, 2007 - wjgnet.com METHODS: Eleven patients were treated with TDF 75 mg for a median period of 80
(range, 24-576) wk and then 7 cases were shifted to an adefovir 10 mg treatment
group. All patients had been pre-treated with lamivudine: 5 had YMDD ... Cited by 14 - Related articles - Cached - BL Direct - All 7 versions
Y Yuan, UH Iloeje, J Hay, S Saab - Journal of Managed Care Pharmacy, 2008 - amcp.org ABSTRACT BACKGROUND: As new treatment options for chronic hepatitis B virus
(HBV) become available, evaluations of cost-effectiveness become important.
Entecavir is a deoxyguanine nucleoside analogue approved by the US Food and ... Cited by 12 - Related articles - View as HTML - BL Direct - All 5 versions
